Table 1.
Clinical profiles of the subjects screened by transnasal or transoral endoscopy and clinicopathological characteristics of detected gastric mucosal neoplasia (mean ± SD) n (%)
| Subject screened |
|||
| Total subjects | By transnasal EGD | By transoral EGD | |
| No. of screened subjects | 3324 | 1382 | 1942 |
| Age (yr) | 53.4 ± 15.4 | 53.4 ± 15.4 | 53.5 ± 15.4 |
| Males | 1442 (43.4) | 684 (49.4)a | 758 (39.0) |
| Smokers | 678 (20.4) | 267 (19.3) | 411 (21.1) |
| Helicobacter pylori-infected subjects | 1202 (40.2) | 510 (39.8) | 692 (40.5) |
| CAG-positive subjects | 1360 (40.9) | 560 (40.5) | 800 (41.2) |
| No. of subjects with gastric neoplasia/DR | 55/0.0165 | 23/0.0166 | 32/0.0165 |
| Location of neoplasia (U/M/L) | 20/15/20 | 8/7/8 | 12/8/12 |
| Adenoma cases/DR | 12/0.0036 | 3/0.0022 | 9/0.0046 |
| Location of adenoma (U/M/L) | 2/4/6 | 0/2/1 | 2/2/5 |
| Size of adenoma (mm) | 10.5 ± 7.0 | 9.7 ± 4.0 | 10.8 ± 7.9 |
| Cancer cases/DR | 43/0.0129 | 20/0.0145 | 23/0.0118 |
| Location of cancer (U/M/L) | 18/11/14 | 8/5/7 | 10/6/7 |
| Size of cancer (mm) | 27.3 ± 16.7 | 32.6 ± 19.5a | 22.3 ± 12.8 |
| Morphological cancer type (I-IIa/IIb/IIc-III/Ad) | 12/1/15/13 | 6/1/5/8 | 6/0/12/5 |
| With intestinal-type cancer | 33 (76.7) | 18 (90.0)a | 15 (65.2) |
| Depth of invasion (m/sm/pm-) | 20/10/13 | 5/7/8 | 15/3/5 |
| With early cancer | 30 (69.7) | 12 (60.0) | 18 (78.3) |
a
P < 0.05 vs transoral esophagogastroduodenoscopy (EGD). CAG: Chronic atrophic gastritis; DR: Detection rate; U: Upper third of the stomach; M: Middle third of the stomach; L: Lower third of the stomach.